MIR211

Summary

MIR211 (microRNA 211, HGNC:31588) is a microRNA gene on chromosome 15q13.3.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 406993 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31588
Approved symbol	MIR211
Name	microRNA 211
Location	15q13.3
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-211
Ensembl gene	ENSG00000207702
Ensembl biotype	miRNA
OMIM	613753
Entrez	406993
RNAcentral	URS000075B6A0 — miRNA, 110 nt, 4 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000384969

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000384969 — 1 exons

Exon	Start	End
ENSE00001499976	31065032	31065141

Expression profiles

Bgee: expression breadth broad, 39 present calls, max score 80.20.

Top tissues by expression

39 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	80.20	gold quality
gastrocnemius	UBERON:0001388	76.87	gold quality
placenta	UBERON:0001987	71.89	gold quality
stomach	UBERON:0000945	71.84	gold quality
left adrenal gland cortex	UBERON:0035825	71.19	gold quality
urinary bladder	UBERON:0001255	70.99	gold quality
body of stomach	UBERON:0001161	70.64	gold quality
vagina	UBERON:0000996	70.58	gold quality
esophagus mucosa	UBERON:0002469	70.47	gold quality
lower esophagus muscularis layer	UBERON:0035833	70.15	gold quality
skin of abdomen	UBERON:0001416	68.87	gold quality
minor salivary gland	UBERON:0001830	68.19	gold quality
zone of skin	UBERON:0000014	68.11	gold quality
ascending aorta	UBERON:0001496	67.87	gold quality
skin of leg	UBERON:0001511	67.35	gold quality
endocervix	UBERON:0000458	67.19	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	66.83	gold quality
myometrium	UBERON:0001296	66.73	gold quality
left uterine tube	UBERON:0001303	66.27	gold quality
putamen	UBERON:0001874	66.06	gold quality
Brodmann (1909) area 9	UBERON:0013540	65.83	gold quality
upper lobe of left lung	UBERON:0008952	65.80	gold quality
spleen	UBERON:0002106	65.65	gold quality
cerebellar hemisphere	UBERON:0002245	65.61	gold quality
ectocervix	UBERON:0012249	65.61	gold quality
thoracic mammary gland	UBERON:0005200	65.24	gold quality
anterior cingulate cortex	UBERON:0009835	65.22	gold quality
omental fat pad	UBERON:0010414	65.19	gold quality
left lobe of thyroid gland	UBERON:0001120	64.68	gold quality
left coronary artery	UBERON:0001626	64.53	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• expression may be associated with the progression of oral carcinoma and poor patient outcomes (PMID:18946016)
• these data indicate a critical role for miR-204/211 in maintaining epithelial barrier function and cell physiology. (PMID:20056717)
• these results provide evidence that the TT genotype (rs2507800) in the 3’-UTR of angiopoietin-1 might reduce the risk of stroke by interfering with miR-211 binding. (PMID:20378606)
• Findings show that miR-211 is a direct posttranscriptional regulator of KCNMA1 expression. (PMID:21072171)
• Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma (PMID:21109473)
• a model for the apparent non-overlapping expression levels of BRN2 and MITF in melanoma, mediated by miR-211 expression. (PMID:21435193)
• identified a series of differentially expressed miRNAs that could be useful as diagnostic or prognostic markers for melanoma and have shown that three miRNAs (namely miR-200c, miR-205 and miR-211) act as tumour suppressors (PMID:22223089)
• the association of between miR-211-regulated CHD5 expression and CHD5 function in colorectal tumorigenesis (PMID:22235338)
• MITF is a key regulator of RPE differentiation that was also down-regulated in dedifferentiated hfRPE cells. MITF knockdown decreased miR-204/211 expression and caused hfRPE dedifferentiation. (PMID:22523078)
• Authors found an acute inhibitory effect of miR-211 on glioma cell invasion and migration via suppression of MMP-9. (PMID:23183822)
• novel role for miR-211 in the regulation of TGFbetaRII and c-Myc during tumorigenesis being revealed should help to develop anti-head and neck squamous cell carcinoma therapies (PMID:23726841)
• We demonstrate that miR-211 contributes to melanoma adhesion by directly targeting a gene, NUAK1. (PMID:23934065)
• miR-211 expression was reduced in most but not all melanoma cell lines and patient samples compared to normal melanocytes, confirming the generally reported reduction of miR-211 levels in melanoma samples. (PMID:24039954)
• High serum miR211 levels are associated with atherosclerosis. (PMID:24848278)
• For the first time, we demonstrate that miRNA-211 is a direct negative regulator of CDC25B expression in TNBC cells, alters other related target proteins CCNB1 and FOXM1, and then inhibits breast cancer cells growth, migration, and invasion (PMID:25680404)
• MiR-211 is a tumor suppressor that controls expression of Cyclin D1 and CDK6. (PMID:25889927)
• Our results suggest for the first time that miR-211 expressed more in colorectal cancer patients than in healthy group could be a new prognostic biomarker in order to predict survival (PMID:26152286)
• miR-211 may function as an oncogenic miRNA in non-small cell lung cancer, partly by regulating SRCIN1 (PMID:26277787)
• Our results indicate that overexpression of miR-211 suppresses the differentiation of bone marrow derived stem cells into intestinal ganglion cells by directly down-regulating the expression of glial-derived neurotrophic factor (PMID:26510977)
• miR-204 and miR-211 directly repress PPM1K expression via 3’UTR. (PMID:26592513)
• Western blot analysis and quantitative real-time polymerase chain reaction demonstrated reduced expression of pri-miR-211, miR-211, TRPM1, and MLANA levels, after Bcl-2 overexpression, associated with increased expression of well-known miR-211 target genes. (PMID:26599548)
• IL-10Ralpha expression is post-transcriptionally regulated by miR-15a, miR-185, and miR-211 in melanoma (PMID:26631117)
• involvement of miR-211 in the regulation of mitochondrial energy metabolism in human melanoma cells (PMID:26787841)
• miR-211 could inhibit gastric cancer cell proliferation and invasion partially by down-regulating SOX4. (PMID:26823713)
• results support miR-211 as a leading miRNA candidate for melanoma diagnosis (PMID:26916074)
• lncRNA-uc002kmd.1 regulates CD44 as a molecular decoy for miR211-3p. (PMID:26974151)
• These results indicate that miR-204/211 serve to increase cell proliferation at least in MCF-7 and MDA-MB-231 breast cancer cells by downregulating tumor suppressor genes. (PMID:27121770)
• STAT3/miR-211/STAT5A signaling plays a key role in mesenchymal stem cell migration. (PMID:27145179)
• MiR-211 is down-regulated in melanoma due to DNMT1 mediated promoter methylation.MiR-211 can modulate epithelial-mesenchymal transition of melanoma cells. (PMID:27237979)
• Data indicate that microRNA miR-211 can directly target the 3’UTR of mucin-4 (MUC4) and inhibit its expression at both mRNA and protein levels. (PMID:27923652)
• Findings indicate that miR-211-mediated inhibition of SNAIL1 expression contributes to the suppression of renal cell carcinoma progression. (PMID:28057716)
• ZEB2 expression was higher in HCC tissues and was negatively related to miR-211-5p levels. (PMID:28437884)
• miR-211, a known transcriptional target of MITF, is induced in melanotic melanoma cells, where it targets EDEM1 and consequently impairs the degradation of TYROSINASE (TYR) through the ER-associated degradation (ERAD) pathway. (PMID:28445987)
• Findings collectively demonstrate a tumour suppressor role of miR-211-5p in triple negative breast cancer progression by targeting SETBP1. (PMID:28571042)
• Studied the association between miR-211-5p and SOX11 in regards to proliferation, viability, and invasion of human thyroid cancer (TC) cells. Found miR-211-5p was upregulated and SOX11 was downregulated in TC tissues and cell lines, and found By inhibiting SOX11, miR-211- 5p suppressed the proliferation and invasion of the TC cells. (PMID:28703321)
• NEAT1 facilitates cell growth and invasion via the miR-211/HMGA2 axis in breast cancer (PMID:28720546)
• The microRNA miR-211/BDNF axis regulates LPS-induced normal human astrocytes proliferation through PI3K/AKT pathway . (PMID:28790168)
• miR211 regulates mitochondrial energy metabolism in patients with vitiligo. (PMID:28843294)
• Overexpression of miR204/211 reduced the migration of EA.hy926 cells in vitro. (PMID:28901393)
• miR211 may act as a tumor suppressor in cervical cancer by directly targeting ZEB1. (PMID:29115509)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
danio_rerio	dre-mir-204-2	ENSDARG00000081512
rattus_norvegicus	Mir211	ENSRNOG00000035648

Paralogs (1): MIR204 (ENSG00000207935)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.